Rilonacept

ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS

Key facts

Rilonacept is a drug catalogued in DrugCentral. It was first approved by the FDA in 2008. DrugCentral lists 3 molecular targets, including IL1B, IL1A and IL1RN. Recorded indications include Cryopyrin associated periodic syndrome.

• Molecular targets: IL1B, IL1A and IL1RN (3 listed in DrugCentral).
• Indications: Cryopyrin associated periodic syndrome.
• ATC code: L04AC04 (Interleukin inhibitors).

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (1)

• Cryopyrin associated periodic syndrome

Mechanism & targets

Molecular targets (3)

Target	Gene	Action	Activity
Interleukin-1 beta	IL1B	inhibitor	Kd 12.30
Interleukin-1 alpha	IL1A	inhibitor	Kd 11.85
Interleukin-1 receptor antagonist protein	IL1RN	inhibitor	Kd 11.21

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
2008-02-27	FDA	—	REGENERON PHARMACEUTICALS

ATC classification

ATC code	Therapeutic hierarchy
L04AC04	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › IMMUNOSUPPRESSANTS › IMMUNOSUPPRESSANTS › Interleukin inhibitors

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Injection site erythema	178.2
Injection site reaction	103.2
Injection site rash	87.9
Chest pain	81.4
Product dose omission issue	80.3
Injection site pain	79.4
Injection site mass	78.4
Injection site pruritus	73.2
Injection site haemorrhage	44.8

Chemical structure

• Molecular formula: —
• Molecular weight: —
• CAS number: 501081-76-1
• InChIKey: —
• PubChem CID: —

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Rilonacept used for?

DrugCentral lists the following indications for Rilonacept: Cryopyrin associated periodic syndrome.

How does Rilonacept work?

Its molecular targets in DrugCentral include IL1B (inhibitor), IL1A (inhibitor) and IL1RN (inhibitor).

When was Rilonacept first approved?

Rilonacept was first approved by the FDA in 2008.

Sources

• DrugCentral drug card 5105 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL1201830 — compound record and bioactivity
• DrugBank DB06372 — drug record
• FDA UNII 8K80YB5GMG — substance identity
• DailyMed: FDA labels for Rilonacept — current prescribing information (label search)
• UniProt P01584 (IL1B) — target protein
• UniProt P01583 (IL1A) — target protein
• UniProt P18510 (IL1RN) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.